FDA 483 - Concord Biotech Limited - May 02, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Concord Biotech Limited in Dholka Ahmedabad, India, revealed significant deficiencies in manufacturing practices for Active Pharmaceutical Ingredients (API). Observations included inadequate equipment cleaning, insufficient laboratory controls for microbiological testing verification, and poor data integrity controls for computerized systems. Additionally, the firm failed to properly monitor and control water quality used in API manufacturing steps.
ID · ca5090cf-c290-4f3a-a498-cd2fd7f95cba